Pharmaceutical Monitoring of Adverse Reactions of Type 1 Diabetes Induced by Cardonilimab
10.3870/j.issn.1004-0781.2025.05.019
- VernacularTitle:卡度尼利单抗致1型糖尿病不良反应的药学监护
- Author:
Dandan WU
1
;
Min XIE
;
Shaowei SUN
;
Ruixia LI
;
Chao SUN
;
Minghua LIU
Author Information
1. 滨州医学院附属医院药学部,滨州 256603
- Publication Type:Journal Article
- Keywords:
Cardonilimab;
Diabetes;
Clinical pharmacist;
Pharmaceutical services
- From:
Herald of Medicine
2025;44(5):791-795
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the identification of adverse reactions of type 1 diabetes during lung cancer treat-ment with cardonilimab and the pharmaceutical monitoring of patient's blood glucose management,and to accumulate ex-perience for the prevention,treatment,and pharmaceutical services of related diseases.Methods The clinical pharmacist assisted doctors in judging adverse drug reactions and identifying suspicious drugs in a patient with lung cancer who devel-oped type 1 diabetes.At the same time,the clinical pharmacist provided suggestions for clinical treatment by referring to clinical evidence,and providing medication education,pharmaceutical care,and long-term follow-up for the patient's blood glucose management.Results After intensive insulin therapy and dietary control,the patient's high glucose symptoms were relieved,and the blood glucose gradually stabilized.The patient continued to be challenged using cardonilimab immu-notherapy,and the condition was stable.Conclusions Clinical pharmacists assist physicians in identifying adverse drug reactions on time and participate in the full process management of patient medication.They play an active therapeutic role in the medical team and reflect the value of pharmaceutical services.
